Saeki K, Wake K, Yamasaki H
Arch Int Pharmacodyn Ther. 1976 Jul;222(1):132-40.
Histamine was injected subcutaneously to rats at doses of 2--10 mg/kg, twice daily for various periods after an intradermal adjuvant injection into one hind paw. The administration of histamine prevented the appearance of the secondary lesion in the noninjected paw, but did not affect the primary swelling of the injected paw or the established secondary lesion. The histamine effect was dose-dependent with the most effective time of administration being from the 5th to the 10th day after adjuvant injection. Arthritic lesions found in control animals in histological and roentgenographic examinations were also inhibited in histamine-treated animals. Sinomenine, a histamine releaser, likewise showed a suppressive effect on the secondary lesion. Burimamide, a histamine H2-receptor antagonist, blocked these histamine effects, while mepyramine, a H1-receptor antagonist, did not have such a blocking effect. The findings suggest that histamine may inhibit the development of adjuvant arthritis by an immunosuppressive mechanism mediated through activation of H2-receptors on lymphoid cells.
在大鼠一侧后爪皮内注射佐剂后的不同时间段，每天两次皮下注射组胺，剂量为2 - 10毫克/千克。组胺的给药可防止未注射爪子出现继发性病变，但不影响注射爪子的原发性肿胀或已形成的继发性病变。组胺的作用呈剂量依赖性，最有效的给药时间是在佐剂注射后的第5至10天。组织学和X线检查中在对照动物中发现的关节炎病变在组胺处理的动物中也受到抑制。组胺释放剂青藤碱同样对继发性病变有抑制作用。组胺H2受体拮抗剂布立马胺可阻断这些组胺作用，而H1受体拮抗剂美吡拉敏则没有这种阻断作用。这些发现表明，组胺可能通过激活淋巴细胞上的H2受体介导的免疫抑制机制来抑制佐剂性关节炎的发展。
